Skip to content
Menu

Abbott Laboratories ABT

Full chart Compare
Set alert

Price alert · ABT

All alert types
103.00 USD -0.87 (-0.84%)

Regular-session close

103.00 0.00 0.00%

After hours · Nov 20, 7:46 PM ET

102.80 Day range 105.50
82.56 52-week range 128.90
YTD
-17.79%
1 year
-16.92%

5D -6.62 (-6.03%)

104106108110MonTueWedThuFri103.20
Market cap
178.39B
Revenue (ttm)
48.23B
Profit margin
9.75%
EPS (ttm)
2.68
Shares out
1.73B
P/E ratio
38.43
Forward P/E
17.33
Dividend
2.52 (2.43%)
Ex-dividend date
Oct 15, 2026
YTD return
-17.79%
1-year return
-16.92%
Volume
7.30M
Avg volume
8.93M
Open
104.32
Previous close
103.87
Day's range
102.80 – 105.50
52-week range
82.56 – 128.90
Beta
0.54
Analysts
Strong Buy
Price target
119.60 (+16.1%)
Earnings date
Jan 28, 2027
50-day average
103.87

Key statistics

200-day average
101.48
Enterprise value
207.63B
PEG ratio
1.50
Price / sales
3.69
Price / book
3.49
Payout ratio
92.54%
Revenue growth
14.50%
Free cash flow
6.07B
Total cash
4.30B
Total debt
31.44B
Return on equity
9.14%
Short % of float
1.23%

Fundamental scorecard

16 of 25 checks passed on ABT’s reported financials

ValueGrowthProfitabilityHealthDividend

16of 25 checks passed

  • Value 2 of 5
  • Growth 4 of 5
  • Profitability 3 of 5
  • Financial health 3 of 5
  • Dividend 4 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ABT Revenue — quarterly 13.01B
ABT Net income — quarterly 920.00M
ABT EPS — quarterly 0.53

Earnings

ABT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 28, 2027Dec 30, 20261.64———
Oct 21, 2026Sep 30, 20261.421.420.000.00%
Jul 16, 2026Jun 30, 20261.281.31+0.03+2.34%
Apr 16, 2026Mar 31, 20261.141.15+0.01+0.88%
Jan 22, 2026Dec 31, 20251.501.500.000.00%
Oct 15, 2025Sep 30, 20251.301.300.000.00%

Upgrades / downgrades

ABT analyst upgrades and downgrades
DateFirmActionFromTo
Nov 19, 2026Leerink PartnersupMarket PerformOutperform
Oct 27, 2026Argus ResearchdownBuyHold
Oct 23, 2026Wells FargomainOverweightOverweight
Oct 22, 2026CitigroupmainBuyBuy
Oct 22, 2026RBC CapitalmainOutperformOutperform
Oct 22, 2026Wells FargomainOverweightOverweight

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
abbott.com

News

Your note

Sign in to keep a note on ABT — it syncs with the Stock Master app.

Insider holders

ABT insider holders
InsiderRelationLatest transactionDateShares held
ALLEN HUBERT L.OfficerStock Award(Grant)Feb 24, 2025200,281
BOUDREAU PHILIP PChief Financial OfficerPurchaseApr 22, 20260
CONROY KEVIN TDirectorStock Award(Grant)Apr 23, 2026133,737
EARNHARDT LISA DOfficerStock Award(Grant)Feb 23, 202698,984
FORD ROBERT B.Chief Executive OfficerConversion of Exercise of derivative securityAug 24, 2026522,664
MORELAND MARY KOfficerSaleMar 1, 2026116,136

Institution ownership

ABT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.76%151,666,06515.60BSep 29, 2026
Vanguard Capital Management LLC6.54%113,251,89911.65BSep 29, 2026
State Street Corporation4.70%81,431,1108.38BSep 29, 2026
Charles Schwab Investment Management, Inc.3.30%57,160,7505.88BSep 29, 2026
Vanguard Portfolio Management LLC2.77%47,941,5434.93BSep 29, 2026
Capital Research Global Investors2.60%44,980,8464.63BSep 29, 2026

Fund ownership

ABT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.19%55,297,2795.69BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF2.75%47,631,7454.90BAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%45,138,4904.64BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%23,056,9072.37BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%22,487,9912.31BSep 29, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%21,408,9182.20BSep 29, 2026